The data we present here clearly show that dipyridamole (a pan‐PDE inhibitor) and cilostazol (a PDE3 inhibitor) can abrogate SREBP2 cleavage and activation in AML and MM cells exposed to a statin. Here, SREBF2 is linked to acute myeloid leukemia.